# OnCo record pancreatic-acinar-cell-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "pancreatic-acinar-cell-carcinoma" ;
  schema:name "Pancreatic acinar cell carcinoma"@en ;
  schema:alternateName "Acinar cell carcinoma"@en, "ACC of the pancreas"@en, "Acinar carcinoma"@en, "Mixed acinar-neuroendocrine carcinoma"@en ;
  schema:description "Pancreatic acinar cell carcinoma is a rare pancreatic cancer that grows from the enzyme-making cells rather than the ducts. It forms large soft masses, can pour lipase into the blood and cause fat lumps under the skin and joint pain, usually lacks the KRAS mutation, often carries DNA repair faults or BRAF fusions, and responds better to bowel-cancer-style chemotherapy than to gemcitabine."@en ;
  schema:url <https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acinar_cell_carcinoma_of_the_pancreas> ;
  schema:citation <https://en.wikipedia.org/wiki/Acinar_cell_carcinoma_of_the_pancreas>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/pancreatoblastoma/>, <https://onco.cc/cancers/pancreatic-net/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/oligometastatic/> ;
  onco:people <https://onco.cc/people/eileen-oreilly/>, <https://onco.cc/people/anirban-maitra/>, <https://onco.cc/people/richard-schulick/> ;
  onco:pipeline <https://onco.cc/technologies/pdac-organoid-pharmacotyping/>, <https://onco.cc/technologies/cgp/> ;
  onco:standardOfCare <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/hrd/> .